Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Arrowhead Pharmaceuticals ( (ARWR) ) just unveiled an announcement.
Douglass Given, M.D., Ph.D., is retiring from Arrowhead Pharmaceuticals’ Board of Directors after fourteen years of service, effective December 31, 2024. The company plans to appoint Douglas S. Ingram, CEO of Sarepta Therapeutics, to the Board in early 2025, coinciding with the closing of their Exclusive License and Collaboration Agreement with Sarepta.
More about Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a company engaged in the biotechnology industry, focusing on the development of RNA interference (RNAi) therapeutics. Their primary market focus is on creating treatments for diseases with high unmet medical needs.
YTD Price Performance: -27.22%
Average Trading Volume: 1,375,139
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.77B
See more data about ARWR stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue